

**Correction to
Lancet Oncol 2018;
19: 1569–78**

Malagón T, Kulasingham S, Mayrand M-H, et al. Age at last screening and remaining lifetime risk of cervical cancer in older, unvaccinated women: a modelling study. *Lancet Oncol* 2018; **19**: 1569–78—The title of this Article was incorrect and should read “Age at last screening and remaining lifetime risk of cervical cancer in older, unvaccinated women: a modelling study”. This correction has been made to the online version as of Jan 3, 2019.

**Correction to
Lancet Oncol 2018;
19: 1590–601**

Gibson TM, Mostoufi-Moab S, Stratton KL, et al. Temporal patterns in the risk of chronic health conditions in survivors of childhood cancer diagnosed 1970–99: a report from the Childhood Cancer Survivor Study cohort. *Lancet Oncol* 2018; **19**: 1590–601—In this Article, the second sentence of the Introduction should read “More than 80% of children diagnosed with a malignancy now achieve 5-year survival, but these individuals have substantial risks of morbidity and mortality later in life because of the late effects of cancer and its treatments”. The final sentence of the first paragraph of the Methods should read “The institutional review boards of the participating institutions approved the CCSS protocol, and participants provided written informed consent to participate in the CCSS study and to be part of research studies using the cohort”. This correction has been made to the online version as of Jan 3, 2019.

**Correction to
Lancet Oncol 2018;
19: 1654–67**

Solomon BJ, Besse B, Bauer TM, et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. *Lancet Oncol* 2018; **19**: 1654–67—In this Article, the name of one of the authors, Professor Sai-Hong Ignatius Ou, should have been listed in the margin affiliation details as: Prof S-H I Ou. This correction has been made to the online version as of Jan 3, 2019.

Correction to *Lancet Oncol* 2018; 19: 1680–87

Vergote I, Coens C, Nankivell M, et al. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. *Lancet Oncol* 2018; **19**: 1680–87—The EORTC and MRC CHORUS study investigators list has been corrected as of Jan 3, 2019.

**Correction to
Lancet Oncol 2019;
20: 43–56**

Moreno C, Greil R, Demirkan F, et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (ILLUMINATE): a multicentre, randomised, open-label, phase 3 trial. *Lancet Oncol* 2019; **20**: 43–56—On figure 3, “del11p” has been corrected to “del11q”, the 95% CI for the hazard ratio for age 65 years or greater has been corrected to “0.12–0.37”, and the 95% CI for the hazard ratio for bulky disease of at least 5 cm has been corrected to “0.08–0.40”. These corrections have been made to the online version as of Jan 3, 2019 and the printed version is correct.

**Correction to
Lancet Oncol 2019;
20: 88–99**

Mamounas EP, Bando H, Lembersky BC, et al. Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol* 2019; **20**: 88–99—The title of this Article should read “Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial”. This correction has been made to the online version as of Jan 3, 2019, and the printed version is correct.